Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 149 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/10/2007 First Published: 2/1/2000


1.		Phase III Randomized Study of Radiotherapy Combined With Temozolomide Versus Carmustine or Lomustine in Patients With Anaplastic Astrocytoma or Mixed Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				RTOG-9813 ECOG-R9813, NCCTG-RTOG-9813, RTOG-98-13, NCT00004259

Last Modified: 1/29/2008 First Published: 10/1/2000


2.		Phase III Randomized Study of Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 70								EORTC-26981 CAN-NCIC-CE3, EORTC-22981, NCT00006353, CE3

Last Modified: 11/7/2006 First Published: 7/1/2001


3.		Phase III Randomized Study of Temozolomide With or Without Whole Brain Radiotherapy in Patients With Stage IV Melanoma With Asymptomatic Brain Metastasis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				EORTC-18981 NCT00020839


4.		Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				EDOAGL-8725-001 A5921009, NCT00068952


5.		Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				C-100-21 NCT00039000


6.		Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267AM2)(COMPLETED)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				P03267 NCT00091572

Last Modified: 6/13/2007 First Published: 12/22/2004


7.		Phase III Randomized Study of Temozolomide Versus Dacarbazine in Patients With Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other, Pharmaceutical / Industry				EORTC-18032 SPRI-PO3267, NCT00101218, EUDRACT-2004-000654-23


8.		Phase 3 Trial of CP-675,206 Versus Either Dacarbazine or Temozolomide in Patients Without Prior Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				A3671009 NCT00257205

Last Modified: 7/26/2005 First Published: 6/1/2000


9.		Phase I/II Study of Temozolomide and Thalidomide in Patients With Advanced Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				MSKCC-99103 NCI-G00-1786, NCT00005815

Last Modified: 5/12/2006 First Published: 7/1/2000


10.		Phase I/II Study of Temozolomide in Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and under				NCI				DUMC-1735-04-9R5 DUMC-1735-02-9R3, DUMC-1735-01-9R2, DUMC-1833-99-10, NCI-G00-1796, NCT00005952

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute